Social Media Analysis Reveals Mixed Mental Health Experiences with GLP-1 Drugs Like Ozempic | Research

The takeaway

Analysis of 43,710 social media posts about GLP-1 drugs found reports of both improved and worsened mood, anxiety, sleep, and addictive behaviors — with insomnia (620 mentions), anxiety (353), and depression (204) as the most discussed mental health concerns.

620 insomnia mentions across 43,710 posts
Insomnia was the most discussed mental health concern among GLP-1 drug users on social media, followed by anxiety (353) and depression (204), alongside reports of improved mood and reduced addictive behaviors

What the researchers found

Out of 43,710 total comments, 620 mentioned insomnia, 353 anxiety, and 204 depression related to GLP-1 RAs.

Why it matters

Understanding the mental health implications of GLP-1 receptor agonists is crucial as their popularity rises. This research sheds light on potential risks and benefits that need to be addressed.

How the study worked

A mixed-methods approach was used, analyzing comments from social media platforms like Reddit, YouTube, and TikTok.

What this study cannot tell us

The study relies on social media data, which may not represent the broader population's views and lacks clinical validation.

How to read the evidence

This is a social media analysis — the lowest tier of evidence quality. While it provides valuable real-world signal detection from 43,710 posts, social media data is self-reported, non-verified, subject to selection bias, and cannot establish causation. It is best viewed as hypothesis-generating research.

When this study was published

Published in 2023, this study captured social media discussion during the peak of the 'Ozempic era' and addresses mental health concerns that continue to be actively investigated by regulatory agencies.

The bigger picture

As GLP-1 drugs become some of the most prescribed medications worldwide, understanding their full impact on mental health is critical. The brain is rich in GLP-1 receptors, and these drugs are known to affect appetite, reward pathways, and potentially mood through central nervous system mechanisms. The European Medicines Agency investigated suicide signals with GLP-1RAs in 2023, finding no definitive link. However, social media data captures real-time patient experiences that traditional pharmacovigilance may miss. This study provides an important complementary data source as tens of millions of new patients start these drugs.

Questions still open

Do GLP-1 drugs directly affect mood through central GLP-1 receptor modulation, or are mental health changes secondary to rapid weight loss and body image shifts?
Which patient subgroups are most vulnerable to negative mental health effects from GLP-1RAs?
Could the positive effects on addictive behaviors reported by some users be therapeutically leveraged for substance use disorders?

Common questions

Can Ozempic cause depression or anxiety?

This social media analysis found that some GLP-1 drug users reported new or worsened depression and anxiety, while others reported improvements in mood. The relationship is complex — weight loss itself can affect mood positively or negatively, and the drugs act on brain receptors involved in reward and mood. Regulatory agencies have investigated these signals and not found definitive evidence of increased suicide risk. If you experience mood changes on a GLP-1 drug, discuss them with your doctor.

Do GLP-1 drugs affect sleep?

Insomnia was the most commonly discussed mental health concern in this social media analysis (620 mentions out of 43,710 posts). Some users reported sleep difficulties after starting GLP-1 drugs. The mechanism isn't clear — it could be related to the drugs' effects on brain GLP-1 receptors, gastrointestinal side effects, or changes in eating patterns. If you experience sleep problems, talk to your prescriber about timing and dosing adjustments.

Read the original research

GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach.

Brain sciences, 13(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Arillotta, Davide; Floresta, Giuseppe; Guirguis, Amira; Corkery, John Martin; Catalani, Valeria; Martinotti, Giovanni; Sensi, Stefano L; Schifano, Fabrizio. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach.. Brain sciences, 13(11). https://doi.org/10.3390/brainsci13111503